Corporate R&D and Productivity in Germany and the United Kingdom

The paper analyzes differences in research and development (R&D) spending and in the impact of R&D on productivity between German and UK firms. Using a dynamic production function approach, the authors find that the R&D output elasticity is approximately the same in both countries, implying a much larger rate of return on R&D in the UK than in Germany.

Corporate R&D and Productivity in Germany and the United Kingdom

The paper analyzes differences in research and development (R&D) spending and in the impact of R&D on productivity between German and UK firms. Using a dynamic production function approach, the authors find that the R&D output elasticity is approximately the same in both countries, implying a much larger rate of return on R&D in the UK than in Germany.

Investment, R&D and Financial Constraints in Britain and Germany

The study tests for the importance of cash flow on investment in fixed capital and research and development (R&D) using firm-level panel data in Great Britain and Germany. Results suggest that financial constraints are more significant in Britain, that they affect the decision to engage in R&D rather than the level of R&D spending by participants, and that consequently the British firms that do engage in R&D are a self-selected group where financing constraints tend to be less binding.

Investment, R&D and Financial Constraints in Britain and Germany

The study tests for the importance of cash flow on investment in fixed capital and research and development (R&D) using firm-level panel data in Great Britain and Germany. Results suggest that financial constraints are more significant in Britain, that they affect the decision to engage in R&D rather than the level of R&D spending by participants, and that consequently the British firms that do engage in R&D are a self-selected group where financing constraints tend to be less binding.

Model of R&D Valuation and the Design of Research Incentives

The authors develop a real options model of research and development (R&D) valuation, which takes into account the uncertainty in the quality of the research output, the time and cost to completion, and the market demand for the R&D output. The model is then applied to study the problem of pharmaceutical under-investment in R&D for vaccines to treat diseases affecting the developing regions of the world.